Programmed cell death ligand-1 blockade in urothelial bladder cancer: To select or not to select

Journal of Clinical Oncology

Volumn 34, Issue 26, 2016, Pages 3115-3116

  Drake, Charles G ^a   Bivalacqua, Trinity J ^a   Hahn, Noah M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

BLADDER CANCER; CANCER IMMUNOTHERAPY; EDITORIAL; HUMAN; IMMUNOCOMPETENT CELL; MELANOMA; METASTASIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; BLADDER TUMOR; CELL DEATH; TRANSITIONAL CELL CARCINOMA; URINARY TRACT TUMOR;

B7-H1 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CELL DEATH; HUMANS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84989827378     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.4696     Document Type: Editorial

References (8)

1. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
2. Sternberg CN, Donat SM, Bellmunt J, et al: Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69:62-79, 2007 (suppl 1)
3. Massard C, Gordon MS, Sharma S, et al: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34:3119-3125, 2016
4. McLaughlin J, Han G, Schalper KA, et al: Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2: 46-54, 2016
5. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
6. Callea M, Albiges L, Gupta M, et al: Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 3:1158-1164, 2015
7. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
8. Ghasemzadeh A, Bivalacqua TJ, Hahn NM, et al: New strategies in bladder cancer: A second coming for immunotherapy. Clin Cancer Res 22:793-801, 2016